Share on StockTwits

Arrhythmia Research Technology (NYSE:HRT) Director Jason Russell Chambers sold 5,000 shares of Arrhythmia Research Technology stock on the open market in a transaction dated Thursday, August 14th. The stock was sold at an average price of $7.30, for a total value of $36,500.00. Following the transaction, the director now directly owns 100,043 shares of the company’s stock, valued at approximately $730,314. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Arrhythmia Research Technology (NYSE:HRT) traded up 0.55% on Thursday, hitting $7.29. The stock had a trading volume of 22,015 shares. Arrhythmia Research Technology has a 52 week low of $2.30 and a 52 week high of $8.00. The stock has a 50-day moving average of $6.75 and a 200-day moving average of $5.61. The company’s market cap is $19.8 million.

Arrhythmia Research Technology, Inc (NYSE:HRT), through its wholly owned subsidiaries has three operating business segments.

Receive News & Ratings for Arrhythmia Research Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrhythmia Research Technology and related companies with Analyst Ratings Network's FREE daily email newsletter.